Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXR Daxor	$11.38 +12.8%	$9.46	$6.55 ▼ $11.38	$55.08M	-0.13	15,642 shs	25,647 shs
INGN Inogen	$7.58 +7.7%	$6.73	$5.70 ▼ $13.33	$203.83M	1.72	283,148 shs	428,143 shs
PROF Profound Medical	$5.56 -1.2%	$5.93	$3.89 ▼ $9.87	$167.08M	0.52	64,491 shs	6,513 shs
SGHT Sight Sciences	$4.25 +3.2%	$3.86	$2.03 ▼ $7.05	$219.73M	2.44	204,298 shs	160,594 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXR Daxor	+0.70%	+4.45%	+8.61%	+40.14%	+14.66%
INGN Inogen	+8.64%	+7.65%	+1.73%	+14.66%	-42.86%
PROF Profound Medical	+1.62%	-0.09%	-3.10%	+31.85%	-39.79%
SGHT Sight Sciences	-2.83%	+18.73%	+20.82%	+20.47%	-30.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DXR Daxor	3.9573 of 5 stars	3.5	5.0	0.0	2.3	1.7	0.0
INGN Inogen	4.1132 of 5 stars	3.3	3.0	3.9	2.0	1.7	1.3
PROF Profound Medical	1.8193 of 5 stars	3.5	1.0	0.0	0.6	2.5	0.6
SGHT Sight Sciences	1.8732 of 5 stars	1.2	4.0	0.0	3.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXR Daxor	3.00	Buy	$25.00	119.68% Upside
INGN Inogen	2.50	Moderate Buy	$11.00	45.12% Upside
PROF Profound Medical	3.00	Buy	$11.00	97.84% Upside
SGHT Sight Sciences	2.43	Hold	$4.27	0.39% Upside

Current Analyst Ratings Breakdown

Latest DXR, SGHT, INGN, and PROF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	SGHT Sight Sciences	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$3.00 ➝ $5.00
7/15/2025	SGHT Sight Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$3.00 ➝ $4.00
6/18/2025	SGHT Sight Sciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.50 ➝ $4.00
6/16/2025	INGN Inogen	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/15/2025	INGN Inogen	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
5/22/2025	INGN Inogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy	$12.00
5/22/2025	SGHT Sight Sciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.20 ➝ $3.60

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXR Daxor	N/A	N/A	N/A	N/A	N/A	N/A
INGN Inogen	$335.70M	0.61	N/A	N/A	$7.30 per share	1.04
PROF Profound Medical	$10.68M	15.64	N/A	N/A	$2.01 per share	2.77
SGHT Sight Sciences	$79.87M	2.75	N/A	N/A	$1.72 per share	2.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXR Daxor	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
INGN Inogen	-$35.89M	-$1.06	N/A	N/A	N/A	-7.58%	-13.77%	-8.52%	N/A
PROF Profound Medical	-$27.82M	-$1.22	N/A	N/A	N/A	-269.35%	-70.41%	-57.22%	8/14/2025 (Estimated)
SGHT Sight Sciences	-$51.51M	-$0.96	N/A	N/A	N/A	-64.23%	-59.38%	-36.43%	N/A

Latest DXR, SGHT, INGN, and PROF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PROF Profound Medical	-$0.43	N/A	N/A	N/A	$4.75 million	N/A
8/7/2025	Q2 2025	INGN Inogen	-$0.22	-$0.15	+$0.07	-$0.15	$90.40 million	$92.28 million
8/7/2025	Q2 2025	SGHT Sight Sciences	-$0.25	-$0.23	+$0.02	-$0.23	$18.18 million	$19.56 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXR Daxor	N/A	N/A	N/A	N/A	N/A
INGN Inogen	N/A	N/A	N/A	N/A	N/A
PROF Profound Medical	N/A	N/A	N/A	N/A	N/A
SGHT Sight Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXR Daxor	N/A	N/A	N/A
INGN Inogen	N/A	3.03	2.67
PROF Profound Medical	0.09	11.31	10.03
SGHT Sight Sciences	0.57	10.01	9.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXR Daxor	1.34%
INGN Inogen	89.94%
PROF Profound Medical	47.86%
SGHT Sight Sciences	55.51%

Insider Ownership

Company	Insider Ownership
DXR Daxor	59.50%
INGN Inogen	1.46%
PROF Profound Medical	1.52%
SGHT Sight Sciences	28.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXR Daxor	37	4.84 million	1.96 million	Not Optionable
INGN Inogen	1,030	26.89 million	26.49 million	Optionable
PROF Profound Medical	150	30.05 million	29.60 million	Optionable
SGHT Sight Sciences	210	51.70 million	36.76 million	Optionable

DXR, SGHT, INGN, and PROF Headlines

Recent News About These Companies

Lake Street Upgrades Sight Sciences (SGHT)

August 11 at 8:32 PM | msn.com

Sight Sciences (NASDAQ:SGHT) Stock Rating Upgraded by Wall Street Zen

August 11 at 2:31 AM | americanbankingnews.com

Wall Street Zen Upgrades Sight Sciences (NASDAQ:SGHT) to Hold

August 10 at 3:32 AM | marketbeat.com

Sight Sciences, Inc. (NASDAQ:SGHT) Q2 2025 Earnings Call Transcript

August 9 at 12:54 PM | msn.com

Sight Sciences (NASDAQ:SGHT) Upgraded to Buy at Lake Street Capital

August 9 at 9:32 AM | marketbeat.com

Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Sight Sciences Reports Q2 2025 Financial Results

August 8, 2025 | tipranks.com

Compared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key Metrics

August 7, 2025 | zacks.com

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

August 7, 2025 | zacks.com

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

August 7, 2025 | globenewswire.com

Sight Sciences (SGHT) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% ...

July 30, 2025 | manilatimes.netM

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

July 30, 2025 | globenewswire.com

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

July 29, 2025 | globenewswire.com

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

July 24, 2025 | globenewswire.com

Sight Sciences, Inc. (NASDAQ:SGHT) Given Consensus Rating of "Hold" by Brokerages

July 19, 2025 | marketbeat.com

Wall Street Zen Downgrades Sight Sciences (NASDAQ:SGHT) to Sell

July 19, 2025 | marketbeat.com

7SGHT : The Analyst Verdict: Sight Sciences In The Eyes Of 4...

July 15, 2025 | benzinga.com

Sight Sciences (NASDAQ:SGHT) Given New $4.00 Price Target at Morgan Stanley

July 15, 2025 | marketbeat.com

Sight Sciences, Inc. (NASDAQ:SGHT) Insider Matthew Link Sells 4,889 Shares

July 8, 2025 | insidertrades.com

SGHT - Sight Sciences Inc Chart - Morningstar

July 5, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DXR, SGHT, INGN, and PROF Company Descriptions

Daxor NASDAQ:DXR

$11.38 +1.29 (+12.78%)

As of 04:00 PM Eastern

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Inogen NASDAQ:INGN

$7.58 +0.54 (+7.67%)

Closing price 04:00 PM Eastern

Extended Trading

$7.60 +0.01 (+0.20%)

As of 04:10 PM Eastern

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Profound Medical NASDAQ:PROF

$5.56 -0.07 (-1.24%)

Closing price 04:00 PM Eastern

Extended Trading

$5.60 +0.04 (+0.72%)

As of 07:01 PM Eastern

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

Sight Sciences NASDAQ:SGHT

$4.25 +0.13 (+3.16%)

Closing price 04:00 PM Eastern

Extended Trading

$4.25 0.00 (0.00%)

As of 04:10 PM Eastern

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time